| |
Overall survival
|
|---|
|
HR
|
95% confidence interval
|
p value
|
|---|
|
Univariate analysis
|
|
Demographic
|
|
Sex (male vs female)
|
0.887
|
0.396–1.987
|
0.770
|
|
Age (< 60 vs 60+)
|
1.461
|
0.625–3.414
|
0.381
|
|
Cytogenetic/clinical factors
|
|
Risk groups (favorable vs intermediate vs adverse)
|
2.325
|
1.183–4.569
|
0.014
|
|
FLT3 (WT vs mutated)
|
1.282
|
0.474–3.466
|
0.624
|
|
Response (NR vs CR)
|
0.213
|
0.089–0.509
|
0.001
|
|
WBC count (low vs high)
|
1.168
|
0.514–2.650
|
0.711
|
|
LDH level (low vs high)
|
0.242
|
0.101–0.584
|
0.002
|
|
Methylation
|
|
CG6 (low vs high)
|
0.894
|
0.386–2.068
|
0.793
|
|
CG7 (low vs high)
|
0.380
|
0.157–0.917
|
0.031
|
|
CG8 (low vs high)
|
0.762
|
0.335–1.731
|
0.516
|
|
CG9 (low vs high)
|
0.331
|
0.136–0.805
|
0.015
|
|
Expression
|
|
DLK1 (low vs high)
|
3.212
|
1.096–9.413
|
0.033
|
|
MEG3 (low vs high)
|
2.294
|
0.819–6.421
|
0.114
|
|
DLK1/MEG3 (low vs high)
|
0.668
|
0.247–1.808
|
0.428
|
|
Multivariate analysis
|
|
Methylation
|
|
CG7 (low vs high)
|
0.533
|
0.185–1.538
|
0.245
|
|
CG9 (low vs high)
|
0.294
|
0.092–0.935
|
0.038
|
|
Expression
|
|
DLK1 (low vs high)
|
1.758
|
0.467–6.615
|
0.404
|
- Low or high refers to values either lower or higher than median calculated for all AML patients included in this study. HR hazard rate, FLT3 FMS-like tyrosine kinase 3, NR non-responders, CR complete remission
